These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

493 related items for PubMed ID: 16452556

  • 1. Adopting orphan drugs--two dozen years of treating rare diseases.
    Haffner ME.
    N Engl J Med; 2006 Feb 02; 354(5):445-7. PubMed ID: 16452556
    [No Abstract] [Full Text] [Related]

  • 2. Rare diseases, orphan drugs, and orphaned patients.
    Scheindlin S.
    Mol Interv; 2006 Aug 02; 6(4):186-91. PubMed ID: 16960139
    [No Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Orphan drugs and orphan tests in the USA.
    Thoene JG.
    Community Genet; 2004 Aug 02; 7(4):169-72. PubMed ID: 15692190
    [No Abstract] [Full Text] [Related]

  • 5. Rare opportunities appear on the horizon to treat rare diseases.
    Torres C.
    Nat Med; 2010 Mar 02; 16(3):241. PubMed ID: 20208483
    [No Abstract] [Full Text] [Related]

  • 6. "Creating hope" and other incentives for drug development for children.
    Connor E, Cure P.
    Sci Transl Med; 2011 Jan 19; 3(66):66cm1. PubMed ID: 21248312
    [Abstract] [Full Text] [Related]

  • 7.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9. Creation and development of the public service orphan drug Human Botulism Immune Globulin.
    Arnon SS.
    Pediatrics; 2007 Apr 19; 119(4):785-9. PubMed ID: 17403850
    [Abstract] [Full Text] [Related]

  • 10.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Incentives for drug development--the curious case of colchicine.
    Kesselheim AS, Solomon DH.
    N Engl J Med; 2010 Jun 03; 362(22):2045-7. PubMed ID: 20393164
    [No Abstract] [Full Text] [Related]

  • 13. The US Orphan Drug Act: rare disease research stimulator or commercial opportunity?
    Wellman-Labadie O, Zhou Y.
    Health Policy; 2010 May 03; 95(2-3):216-28. PubMed ID: 20036435
    [Abstract] [Full Text] [Related]

  • 14. Lucrative niches: how drugs for rare diseases became lifeline for companies.
    Anand G.
    Wall St J (East Ed); 2005 Nov 15; ():A1, A18. PubMed ID: 16502531
    [No Abstract] [Full Text] [Related]

  • 15. How did uncommon disorders become 'rare diseases'? History of a boundary object.
    Huyard C.
    Sociol Health Illn; 2009 May 15; 31(4):463-77. PubMed ID: 19397760
    [Abstract] [Full Text] [Related]

  • 16. A cross-national comparative study of orphan drug policies in the United States, the European Union, and Japan: towards a made-in-China orphan drug policy.
    Liu BC, He L, He G, He Y.
    J Public Health Policy; 2010 Dec 15; 31(4):407-20; discussion 420-1. PubMed ID: 21119648
    [Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20. Experimental use and the Orphan Drug Act: a biotechnology conundrum.
    Koivuniemi PJ.
    Nat Biotechnol; 1996 Apr 15; 14(4):511-2. PubMed ID: 9630930
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 25.